MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

In vivo markers of anxiety in drug-naïve Parkinson’s disease

H. Wilson, E. de Natale, M. Politis (London, United Kingdom)

Meeting: MDS Virtual Congress 2020

Abstract Number: 651

Keywords: Anxiety, Magnetic resonance imaging(MRI), Parkinsonism

Category: Parkinson's Disease: Neuroimaging

Objective: To investigate imaging and CSF markers of disease pathology associated with anxiety in drug-naïve idiopathic Parkinson’s disease (PD) patients.

Background: Anxiety is a frequent symptom appearing early in PD; however, the underlying neuropathology remains unclear. There are limited studies investigating the aetiology of anxiety in early stages of PD.

Method: The Parkinson’s Progression Markers Initiative database was utilised to identify 423 drug-naïve PD patients. The severity of anxiety was assessed using the State-Trait Anxiety Inventory (STAI) based on the 2 subscales; the State Anxiety Scale (S-Anxiety), which evaluates the current state of anxiety, and the Trait Anxiety Scale (T-Anxiety) which evaluates relatively stable aspects of ‘anxiety proneness’. The relationship between grey matter volumetric loss (regional-based morphometry), microstructural changes (diffusion tensor imaging), and CSF biomarkers with S-Anxiety and T-Anxiety was investigated in limbic regions-of-interest, controlling for age, disease duration and depression (geriatric depression scale). P values were FDR corrected.

Results: Based on a cut-off ≥40 for clinically significant anxiety, the prevalence of S-Anxiety was 25% (n=104) and T-Anxiety was 20% (n=85) in the drug-naïve PD patients. Lower CSF amyloid-β42 levels correlated with higher S-Anxiety (r=-0.14; P=0.007) and T-Anxiety (r=-0.16; P=0.004) scores; while lower α-synuclein (r=-0.16; P=0.004) and total tau (r=-0.14; P=0.008) levels correlated with higher S-Anxiety scores. Higher T-Anxiety was associated with decreased fractional anisotropy in the accumbens (r=-0.19; P=0.018), amygdala (r=-0.19; P=0.019), thalamic primary sensory nuclei (r=-0.19; P=0.020), midbrain (r=-0.18; P=0.021) and the temporal cortex (r=-0.21; P=0.011). Grey matter volumetric loss in the temporal (r=-0.12; P=0.023) and insula (r=-0.12; P=0.015) cortex, midbrain (r=-0.15; P=0.003), median raphe (r=-0.13; P=0.011) and locus coeruleus (r=-0.11; P=0.035) correlated with the severity of T-Anxiety.

Conclusion: These results suggest that in early PD anxiety could be associated with structural and microstructural damage in the limbic system and with abnormal protein accumulation.

To cite this abstract in AMA style:

H. Wilson, E. de Natale, M. Politis. In vivo markers of anxiety in drug-naïve Parkinson’s disease [abstract]. Mov Disord. 2020; 35 (suppl 1). https://www.mdsabstracts.org/abstract/in-vivo-markers-of-anxiety-in-drug-naive-parkinsons-disease/. Accessed May 17, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/in-vivo-markers-of-anxiety-in-drug-naive-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley